NS Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

Continue Learn More X

Home » News » Company News » Brattea, a Leading Renal Denervation Company in China, Completes over $US20 Million Series B+ Financing, led by Kuanping Capital » image-1

Brattea, a Leading Renal Denervation Company in China, Completes over $US20 Million Series B+ Financing, led by Kuanping Capital

NS Medical Devices is using cookies

Brattea completes over $20m Series B+ Financing. (Credit: Brattea.)

Related Article

Biggest players in the global wound care market

RECOMMENDED COMPANIES

MOST READ

GE HealthCare launches Voluson Signature 20 and 18 ultrasound systems for women

Lumicell gets FDA nod for LumiSystem breast cancer visualisation system

AtriCure introduces cryoSPHERE+ probe to manage post-operative pain

Scopio Labs gets FDA nod for digital bone marrow aspirate application

Viz.ai, NICO collaborate on improving intracerebral hemorrhage outcomes

Recommended Whitepaper